Roche says cancer setback to be cushioned by other drug development

ZURICH: Roche Chairman Christoph Franz on Thursday said a wide product development pipeline at the Swiss pharma and diagnostics company would offset the loss in growth prospects from a failure in immuno-oncology development this week.
Development of a new cancer treatment pioneered by Roche was thrown into doubt on Wednesday when immunotherapy drug tiragolumab failed to slow progression of lung cancer in a second trial, hitting the Swiss drugmaker’s shares.